Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results

Variant allelic frequency of driver mutations predicts success of genomic DNA methylation classification in central nervous system tumors

(2023) Pouya Jamshidi et al.   ACTA NEUROPATHOLOGICA

MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value

(2023) Henning Leske et al.   Acta Neuropathologica Communications

Validation of Whole Genome Methylation Profiling Classifier for Central Nervous System Tumors

(2022) Lucas Santana-Santos et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas

(2022) Tomohiro Hosoya et al.   JOURNAL OF NEURO-ONCOLOGY

Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy

(2022) J. Gempt et al.   ESMO Open

Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients

(2021) Rocio Rosas-Alonso et al.   Clinical Epigenetics

Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas

(2021) Timothy E Richardson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas

(2021) Craig Horbinski et al.   NEURO-ONCOLOGY

Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma

(2021) Jun-ichi Adachi et al.   Brain Tumor Pathology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

(2021) David N Louis et al.   NEURO-ONCOLOGY

Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics

(2021) Zhichao Wu et al.   NEURO-ONCOLOGY

Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review

(2021) Susana Olmedillas-López et al.   Molecular Diagnosis & Therapy

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

(2020) Michael Weller et al.   Nature Reviews Clinical Oncology

Intra-Tumor DNA Methylation Heterogeneity in Glioblastoma; Implications for DNA Methylation-Based Classification

(2019) Anna Wenger et al.   NEURO-ONCOLOGY

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients

(2019) Anna Estival et al.   Scientific Reports

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

(2018) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience

(2018) David Capper et al.   ACTA NEUROPATHOLOGICA

MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme

(2018) Lorena Gurrieri et al.   Future Oncology

DNA methylation-based classification of central nervous system tumours

(2018) David Capper et al.   NATURE

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide

(2018) Erica H. Bell et al.   JAMA Oncology

Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma

(2018) Damian Stichel et al.   ACTA NEUROPATHOLOGICA

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

(2017) Martin J van den Bent et al.   LANCET

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

(2017) James R. Perry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors

(2016) Pierre Bady et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial

(2016) Véronique Quillien et al.   Oncotarget

Digital PCR quantification ofMGMTmethylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer

(2015) L. Barault et al.   ANNALS OF ONCOLOGY

Withholding temozolomide in glioblastoma patients with unmethylatedMGMTpromoter—still a dilemma?: Table 1.

(2015) Monika E. Hegi et al.   NEURO-ONCOLOGY

TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma

(2015) Mohamed Ali Mosrati et al.   Oncotarget

Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays

(2014) Martin J. Aryee et al.   BIOINFORMATICS

Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR

(2014) Lawrence J. Jennings et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation

(2012) C. G. Duncan et al.   GENOME RESEARCH

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

(2012) Jan Budczies et al.   PLoS One

A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG

(2011) Beth Pietrak et al.   BIOCHEMISTRY

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

(2011) Qi SongTao et al.   CANCER SCIENCE

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

(2011) A. L. Rivera et al.   NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

(2008) Gaspar J. Kitange et al.   NEURO-ONCOLOGY